Department of Urology, Institute of Urology, National Clinical Research Center for Geriatrics and Center of Biomedical Big Data, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.
Department of Molecular Oncology, Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
Chin Med J (Engl). 2024 Jan 20;137(2):209-221. doi: 10.1097/CM9.0000000000002710. Epub 2023 Jun 30.
Bladder cancer, characterized by a high potential of tumor recurrence, has high lifelong monitoring and treatment costs. To date, tumor cells with intrinsic softness have been identified to function as cancer stem cells in several cancer types. Nonetheless, the existence of soft tumor cells in bladder tumors remains elusive. Thus, our study aimed to develop a micro-barrier microfluidic chip to efficiently isolate deformable tumor cells from distinct types of bladder cancer cells.
The stiffness of bladder cancer cells was determined by atomic force microscopy (AFM). The modified microfluidic chip was utilized to separate soft cells, and the 3D Matrigel culture system was to maintain the softness of tumor cells. Expression patterns of integrin β8 (ITGB8), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) were determined by Western blotting. Double immunostaining was conducted to examine the interaction between F-actin and tripartite motif containing 59 (TRIM59). The stem-cell-like characteristics of soft cells were explored by colony formation assay and in vivo studies upon xenografted tumor models.
Using our newly designed microfluidic approach, we identified a small fraction of soft tumor cells in bladder cancer cells. More importantly, the existence of soft tumor cells was confirmed in clinical human bladder cancer specimens, in which the number of soft tumor cells was associated with tumor relapse. Furthermore, we demonstrated that the biomechanical stimuli arising from 3D Matrigel activated the F-actin/ITGB8/TRIM59/AKT/mTOR/glycolysis pathways to enhance the softness and tumorigenic capacity of tumor cells. Simultaneously, we detected a remarkable up-regulation in ITGB8, TRIM59, and phospho-AKT in clinical bladder recurrent tumors compared with their non-recurrent counterparts.
The ITGB8/TRIM59/AKT/mTOR/glycolysis axis plays a crucial role in modulating tumor softness and stemness. Meanwhile, the soft tumor cells become more sensitive to chemotherapy after stiffening, that offers new insights for hampering tumor progression and recurrence.
膀胱癌具有较高的肿瘤复发潜能,需要终身进行监测并接受治疗,因此具有较高的治疗和监测成本。目前,已经在几种癌症类型中发现内在柔软的肿瘤细胞具有癌症干细胞的功能。然而,膀胱癌中是否存在柔软的肿瘤细胞仍然难以确定。因此,我们的研究旨在开发一种微屏障微流控芯片,以从不同类型的膀胱癌细胞中有效分离出可变形的肿瘤细胞。
通过原子力显微镜(AFM)测定膀胱癌细胞的硬度。利用改良的微流控芯片分离柔软的细胞,采用三维 Matrigel 培养系统维持肿瘤细胞的柔软性。通过 Western blot 检测整合素 β8(ITGB8)、蛋白激酶 B(AKT)和哺乳动物雷帕霉素靶蛋白(mTOR)的表达模式。通过双免疫染色检测 F-肌动蛋白(F-actin)和三部分基序包含蛋白 59(TRIM59)之间的相互作用。通过集落形成实验和异种移植肿瘤模型的体内研究探索柔软细胞的类干细胞特性。
使用我们新设计的微流控方法,我们在膀胱癌细胞中鉴定出一小部分柔软的肿瘤细胞。更重要的是,在临床人膀胱癌标本中证实了柔软肿瘤细胞的存在,并且这些柔软肿瘤细胞的数量与肿瘤复发相关。此外,我们证明了 3D Matrigel 产生的生物力学刺激激活了 F-actin/ITGB8/TRIM59/AKT/mTOR/糖酵解途径,从而增强了肿瘤细胞的柔软性和致瘤能力。同时,我们在临床膀胱癌复发性肿瘤中检测到 ITGB8、TRIM59 和磷酸化 AKT 的显著上调,而在非复发性肿瘤中则没有。
ITGB8/TRIM59/AKT/mTOR/糖酵解轴在调节肿瘤柔软性和干性方面发挥着重要作用。同时,柔软的肿瘤细胞在变僵硬后对化疗更加敏感,这为阻碍肿瘤进展和复发提供了新的思路。